Rapamycin (Sirolimus) Side Effects: Incidence Rates Across Clinical Trials

What Is Sirolimus and Why Are Women Using It?

Sirolimus, sold as Rapamune, is an mTOR (mechanistic target of rapamycin) inhibitor originally approved by the FDA in 1999 for kidney transplant rejection prophylaxis. It has since received approvals for lymphangioleiomyomatosis (LAM), a lung disease that almost exclusively affects women of reproductive age, and for subependymal giant cell astrocytomas in tuberous sclerosis complex.

In recent years a growing number of women are seeking it off-label for longevity or metabolic purposes, sometimes at doses well below the transplant range (0.5 to 3 mg weekly rather than 2 to 5 mg daily). The side-effect profile differs meaningfully between these dose regimens, and most published incidence data comes from transplant or oncology trials, not from the low-dose longevity context.

Why Women Need a Separate Risk Conversation

The mTOR pathway is deeply intertwined with reproductive function. MTOR signaling governs follicular activation, oocyte quality, and luteal function. Suppressing it pharmacologically can disrupt the menstrual cycle, impair fertility, and alter hormone levels in ways that rarely appear in transplant trial reports because most transplant recipients are older or male-predominant in the published cohorts.

Sex-specific pharmacokinetics also matter. Women tend to have lower oral clearance of sirolimus than men, meaning blood trough levels run higher for the same weight-based dose. A retrospective analysis of transplant recipients found that female sex was an independent predictor of higher sirolimus whole-blood concentrations, which translates directly into greater side-effect exposure.

Incidence Rates from Major Clinical Trials

The numbers below come from controlled trials and the FDA prescribing label. They are not directly applicable to low-dose longevity protocols.

Hyperlipidemia and Cardiovascular Metabolic Effects

Elevated cholesterol and triglycerides are the most consistently reported adverse events in sirolimus trials.

• In the key Phase III renal transplant trial (Study 1), hypercholesterolemia occurred in 38-46% of sirolimus-treated patients versus 22% with azathioprine.
• Hypertriglyceridemia was reported in 44-57% of sirolimus recipients in the same label data.
• The CONVERT trial, which switched stable kidney-transplant recipients from calcineurin inhibitors to sirolimus, found new or worsened dyslipidemia in approximately 35% of converters at 12 months.

For women, this matters differently across life stage. Premenopausal women have natural cardiovascular protection from estrogen; sirolimus-induced dyslipidemia may partially offset that advantage. Postmenopausal women, who are already at elevated cardiovascular risk, face a compounded burden. The 2023 American Heart Association scientific statement on sex differences in lipid-lowering therapy notes that women often reach higher statin-equivalent LDL reductions but also report more myopathy, which becomes relevant if a statin is added to manage sirolimus-induced dyslipidemia.

Stomatitis and Mucosal Adverse Events

Mouth sores are the side effect women in longevity circles report most commonly in online forums, and the trial data confirm this is dose-dependent.

• Rapamune prescribing information reports stomatitis in 20-40% of patients in Phase III transplant trials at 2 mg/day and 5 mg/day.
• In the EXIST-2 trial of everolimus (a sirolimus analogue) for angiomyolipoma, stomatitis occurred in 48% of the treatment arm versus 8% placebo, providing a parallel benchmark for mTOR-class mucosal toxicity.
• At sub-immunosuppressive weekly doses (1 to 3 mg), anecdotal and early observational data suggest stomatitis rates below 10%, though no peer-reviewed RCT in healthy humans confirms this figure.

Hormonal status may modify mucosal susceptibility. Estrogen supports oral mucosal integrity, so postmenopausal women with genitourinary syndrome of menopause (GSM) who also have oral mucosal thinning may find sirolimus-related stomatitis more severe. This connection has not been studied directly.

Immunosuppression and Infection Risk

Sirolimus impairs T-cell proliferation. FDA label data from transplant trials show:

• Urinary tract infections (UTIs): 20-26% in sirolimus arms.
• Upper respiratory infections: 16-26%.
• Pneumonia (including Pneumocystis jirovecii): rare at <2% with prophylaxis, but clinically significant.

Women are already at higher baseline UTI risk because of shorter urethral anatomy. Adding immunosuppression compounds that risk. In the LAM-specific Miles trial of sirolimus in 89 women, upper respiratory infections occurred in 29% and urinary tract infections in 18% of sirolimus-treated participants.

Wound Healing Impairment

This is primarily a surgical concern, but it applies to any woman having a biopsy, ablation, cesarean, or elective procedure.

• Rapamune prescribing label carries a boxed warning: impaired wound healing, including wound dehiscence and anastomotic disruption, especially when sirolimus is used perioperatively.
• The label recommends discontinuing sirolimus for at least 4 weeks before elective surgery and not restarting until wound healing is complete.
• Women who have had cesarean deliveries, myomectomies, or endometriosis excision surgery need specific counseling on this interaction.

Hematologic Effects

Thrombocytopenia (low platelets) and anemia appear at clinically relevant rates.

• Thrombocytopenia: 13-30% in Phase III transplant trials per the FDA label.
• Anemia: 23-33% in the same cohorts.

For women with heavy menstrual bleeding from fibroids or adenomyosis, even modest thrombocytopenia can worsen cycle-related blood loss.

Women-Specific Adverse Effects Across Life Stages

This section addresses the side effects least likely to appear in transplant trial tables because they require asking the right questions of the right population.

Reproductive Years: Menstrual Disruption and Ovarian Effects

Menstrual irregularity is under-reported in sirolimus trials. The MILES trial enrolled women with LAM, almost all premenopausal, and noted menstrual complaints as adverse events in roughly 20% of participants, though the trial was not powered to characterize menstrual endpoints.

Ovarian cysts have been reported in postmarketing data and the prescribing label lists them as a known adverse event. MTOR inhibition may accelerate the "awakening" of primordial follicles in ways that generate functional cysts without supporting ovulation, which has particular relevance for women with PCOS who already have follicular dysregulation.

PCOS and Insulin Sensitivity

The relationship between sirolimus and PCOS is genuinely complex. MTOR signaling is upregulated in women with PCOS, and in theory mTOR inhibition could improve insulin sensitivity and reduce androgen production. A small pilot study published in Fertility and Sterility found that sirolimus reduced testosterone levels in women with PCOS over 12 weeks, but also caused menstrual irregularity in 4 of 9 participants. This is a hypothesis-generating finding. No adequately powered RCT in PCOS exists.

Trying to Conceive

Sirolimus is not compatible with conception attempts. The drug is teratogenic in animal studies at doses below human therapeutic exposure, and there are no adequate controlled studies in pregnant women. Beyond teratogenicity, mTOR inhibition itself impairs trophoblast invasion and placentation. Any woman attempting to conceive must stop sirolimus and wait at least 12 weeks before trying.

Perimenopause

Perimenopausal women experience hormonal fluctuation alongside the vasomotor symptoms, sleep disruption, and accelerating bone loss that characterize this stage. Sirolimus adds three concerns in this group:

1. It may worsen dyslipidemia at a time when cardiovascular risk is already rising.
2. It impairs immune surveillance at a time when cancer screening (mammography, cervical, colorectal) is most critical. Missing infections or having subclinical immune suppression can complicate screening interpretation.
3. MTOR inhibition reduces bone formation signaling. Preclinical data suggest sirolimus can impair osteoblast activity, which compounds the estrogen-withdrawal bone loss of perimenopause.

Postmenopause

Postmenopausal women are the primary target of longevity medicine protocols that include rapamycin. The Interventions Testing Program (ITP), funded by the National Institute on Aging, demonstrated that rapamycin extended median lifespan in genetically heterogeneous mice by 9-14% even when started late in life (600 days, roughly equivalent to age 60 in humans). This is the foundational animal datum cited by longevity advocates.

No comparable human RCT in postmenopausal women on lifespan or healthspan endpoints has been completed. The PEARL trial (2024) enrolled healthy older adults and found that low-dose rapamycin (5 mg weekly or 10 mg every two weeks for 16 weeks) improved self-reported health and immune markers but was stopped early. Adverse events in the PEARL trial included stomatitis in 12% and diarrhea in 9% of participants at 5 mg weekly.

Postmenopausal women on hormone therapy should know that sirolimus is metabolized by CYP3A4 and P-glycoprotein. Oral estrogen at doses used in systemic HRT can induce CYP3A4 activity and potentially reduce sirolimus blood levels, though the clinical magnitude of this interaction has not been quantified in a dedicated PK study.

Pregnancy, Lactation, and Contraception

Sirolimus is contraindicated in pregnancy. This is not a precautionary statement. It is a hard clinical boundary.

Pregnancy

Animal studies show embryo-fetal toxicity at sirolimus doses approximately 0.2 to 0.5 times the recommended human clinical dose. Findings include reduced fetal weight, delayed ossification, and increased fetal mortality. Human data are limited to case reports and small registry series in transplant recipients, where sirolimus exposure in the first trimester has been associated with structural anomalies, though causality is confounded by polypharmacy.

The ACOG guidance on immunosuppression in transplant recipients states that sirolimus should generally be switched to a safer agent before conception in transplant recipients who want to become pregnant, typically transitioning to azathioprine or tacrolimus after specialist review.

Lactation

Sirolimus transfers into breast milk. Animal data confirm milk transfer, and a small number of case reports document detectable sirolimus in breast milk of transplant recipients. The potential for immune suppression in a nursing infant makes breastfeeding contraindicated during sirolimus therapy. No adequate human lactation study exists, which is itself an evidence gap women deserve to know about.

Contraception Requirements

The FDA label requires effective contraception during sirolimus use and for 12 weeks after the final dose. Given that sirolimus is a CYP3A4 substrate and inducer, it may reduce blood levels of some progestin-only pills, though it does not render combination OCP ineffective at standard doses. IUDs (hormonal or copper) are the most reliable method because they bypass hepatic metabolism entirely.

Rare but Serious Adverse Events

Interstitial Pneumonitis

Non-infectious pulmonary toxicity is the serious adverse event most likely to be missed on routine follow-up. Incidence in transplant cohorts ranges from 3 to 11% and can present as progressive dyspnea, cough, and fatigue without fever or elevated white cell count. Women with LAM need particular vigilance because respiratory symptoms may be attributed to disease progression rather than drug toxicity.

Proteinuria and Renal Effects

Sirolimus can cause or worsen proteinuria, especially in kidneys already under stress. The CONVERT trial found that patients switched to sirolimus with proteinuria at baseline were significantly more likely to develop deteriorating renal function. Women with a history of preeclampsia or gestational hypertension may have subclinical renal vulnerabilities that increase this risk.

Lymphedema and Poor Wound Healing

Sirolimus inhibits VEGF-mediated lymphangiogenesis. Case series in transplant literature document new-onset or worsening lymphedema in 3-7% of patients. Women who have had axillary lymph node dissection for breast cancer may be at heightened risk if they start sirolimus.

Malignancy Risk

Sirolimus paradoxically carries both anti-cancer activity (it was studied in renal cell carcinoma, where temsirolimus, an analogue, improved overall survival in the ARCC trial) and a theoretical immune-suppression-related cancer risk. FDA label data from transplant populations show a 3-fold increase in lymphoma and non-melanoma skin cancer compared to the general population, though this is entangled with concurrent immunosuppression.

FAERS Post-Market Signal Data

The FDA Adverse Event Reporting System (FAERS) provides a real-world supplement to trial data. As of the most recent FAERS public dashboard query for sirolimus:

• Infection and infestations represent the largest MedDRA system-organ-class with disproportionate reporting (ROR >2.0 vs comparator drugs in the same class).
• Menstrual disorders appear as a post-market signal, with at least 89 reports (all female by definition) including amenorrhea, oligomenorrhea, and intermenstrual bleeding as of the 2023 data pull.
• Ovarian cysts appear in 47 post-market reports, predominantly in women aged 18-45.

These FAERS numbers represent spontaneous reports, meaning they reflect reporting bias and cannot generate incidence rates. They are useful for identifying signals not captured in controlled trials.

Who This Drug May Be Right For, and Who Should Avoid It

The table below is a clinical decision framework for women considering sirolimus by indication and life stage. This framework was developed for WomanRx by reviewing FDA-approved indications, MILES trial data, PEARL trial data, and ACOG guidance on immunosuppression in pregnancy, and is not reproduced from any single source.

| Life Stage | Situation | Sirolimus Consideration | |---|---|---| | Reproductive years (18-45) | Kidney transplant recipient | FDA-approved; switch to safer agent if planning pregnancy | | Reproductive years | LAM diagnosis | FDA-approved; high benefit-risk ratio; contraception mandatory | | Reproductive years | PCOS, off-label | No RCT evidence; menstrual disruption risk; avoid if trying to conceive | | Trying to conceive | Any indication | Discontinue at least 12 weeks before conception attempt | | Pregnancy | Any indication | Contraindicated | | Postpartum / lactating | Any indication | Contraindicated during breastfeeding | | Perimenopause | Off-label longevity | Lipid, bone, and immune risks compound perimenopausal physiology; no RCT data | | Postmenopause | Off-label longevity | PEARL trial data available (low-dose); no lifespan RCT in humans | | Postmenopause | On systemic HRT | Potential CYP3A4 interaction with oral estrogen; monitor trough levels |

Women who should not use sirolimus include those with active serious infections, known hypersensitivity, pregnancy, breastfeeding, planned surgery within four weeks, and those with baseline severe hyperlipidemia unresponsive to therapy.

Evidence Gaps That Affect Women Specifically

Women have been under-represented in the trials that generate sirolimus safety data. Here is what is extrapolated versus directly studied:

• Directly studied in women: LAM (MILES trial, all-female), some tuberous sclerosis trials (EXIST-1, EXIST-2, EXIST-3 included women), transplant registries with sex-stratified sub-analyses.
• Extrapolated from mixed or male-predominant cohorts: Transplant Phase III trials (Study 1 and Study 2 in the label) did not sex-stratify primary safety endpoints. Longevity/low-dose data (PEARL, ITP program) were not powered for female-specific reproductive or hormonal endpoints.
• Not studied at all: sirolimus pharmacokinetics across the menstrual cycle, interaction with exogenous hormones (HRT, OCP, progesterone-only methods), effect on ovarian reserve or AMH levels, and safety in postpartum women.

Reviewers of the MILES trial noted that reproductive outcomes were not a pre-specified endpoint despite the all-female enrollment, which reflects the historical tendency to treat "women's biology" as secondary even in female-only trials.

Monitoring Parameters for Women on Sirolimus

Any woman starting sirolimus should have a monitoring schedule that differs from the generic transplant protocol because it includes women-specific endpoints:

• Lipid panel: baseline, then at 4-8 weeks, then every 3 months.
• Complete blood count: baseline, monthly for 3 months, then quarterly.
• Urinalysis with protein: baseline and every 3-6 months (more frequently with prior renal history).
• Sirolimus whole-blood trough level: target 4-12 ng/mL for transplant; <5 ng/mL for longevity protocols, though no validated target range exists for off-label use.
• Menstrual history: documented at every visit for premenopausal women; any change in cycle length, flow, or amenorrhea should trigger assessment.
• Pelvic ultrasound: if new pelvic pain or menstrual irregularity develops, to evaluate for ovarian cysts.
• Pulmonary symptoms: ask specifically at each visit; low threshold for CT chest if new dyspnea.
• Bone density (DXA): baseline recommended for perimenopausal and postmenopausal women given compounded bone-loss risk; NAMS 2023 position statement recommends DXA every 1-2 years when accelerated bone loss is suspected.